View all text of Chapter 7 [§ 271 - § 286]
§ 278u. Xylazine detection and analysis
(a) DefinitionsIn this section:
(1) Director
(2) Federal laboratory
(3) Institute
(4) Institution of higher education
(5) Nonprofit organization
(6) Xylazine
(b) In generalThe Director shall—
(1) support intramural basic measurement science and research of the Institute to advance—
(A) analytical methods to identify, understand, differentiate, and categorize substances containing xylazine, novel synthetic opioids, or other new psychoactive substances;
(B) measurement technologies to shorten analysis timelines and enhance narcotic and opioid detection and analysis capabilities;
(C) new data tools, techniques, and processes to identify and publicly disclose relevant information concerning substances containing xylazine, novel synthetic opioids, or other new psychoactive substances; and
(D) such other areas as the Director determines to be critical to the development and deployment of technologies to measure and analyze the presence of xylazine, novel synthetic opioids, and other new psychoactive substances;
(2) support activities to inform and expand the development of near-real time spectrometry capabilities regarding xylazine, novel synthetic opioids, and other new psychoactive substances;
(3) convene and consult with organizations engaged in the analysis of new psychoactive substances to develop coordinated strategies and voluntary best practices for the safe handling, transport, data-sharing, and analysis of substances containing xylazine, novel synthetic opioids, or other new psychoactive substances, including—
(A) the Drug Enforcement Administration;
(B) the Centers for Disease Control and Prevention;
(C) the National Institute on Drug Abuse;
(D) Federal laboratories;
(E) States and territories;
(F) State fusion centers;
(G) the private sector;
(H) intergovernmental organizations;
(I) institutions of higher education,1
1 So in original. The comma probably should be a semicolon.
and(J) nonprofit organizations;
(4) establish or expand collaborative partnerships or consortia with other government agencies and persons engaged in related research and development, such as institutions of higher education, Federal laboratories, public health agencies, intergovernmental organizations, and the private sector, to enhance narcotic and opioid detection and analysis capabilities regarding xylazine, novel synthetic opioids, and other new psychoactive substances; and
(5) encourage graduate and post-graduate research to include detection and identification of xylazine and other new psychoactive substances in relevant course studies when practicable.
(c) Controls
(d) Report
(Pub. L. 118–23, § 2, Dec. 19, 2023, 137 Stat. 125.)